These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23908479)

  • 1. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults.
    Mullane KM; Winston DJ; Wertheim MS; Betts RF; Poretz DM; Camacho LH; Pergam SA; Mullane MR; Stek JE; Sterling TM; Zhao Y; Manoff SB; Annunziato PW
    J Infect Dis; 2013 Nov; 208(9):1375-85. PubMed ID: 23908479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
    Vermeulen JN; Lange JM; Tyring SK; Peters PH; Nunez M; Poland G; Levin MJ; Freeman C; Chalikonda I; Li J; Smith JG; Caulfield MJ; Stek JE; Chan IS; Vessey R; Schödel FP; Annunziato PW; Schlienger K; Silber JL
    Vaccine; 2012 Jan; 30(5):904-10. PubMed ID: 22154769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies.
    Parrino J; McNeil SA; Lawrence SJ; Kimby E; Pagnoni MF; Stek JE; Zhao Y; Chan IS; Kaplan SS
    Vaccine; 2017 Mar; 35(14):1764-1769. PubMed ID: 28268074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
    Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Eberhardson M; Hall S; Papp KA; Sterling TM; Stek JE; Pang L; Zhao Y; Parrino J; Popmihajlov Z
    Clin Infect Dis; 2017 Oct; 65(7):1174-1182. PubMed ID: 29126292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
    Russell AF; Parrino J; Fisher CL; Spieler W; Stek JE; Coll KE; Su SC; Xu J; Li X; Schlienger K; Silber JL
    Vaccine; 2015 Jun; 33(27):3129-34. PubMed ID: 25964168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults.
    Macaladad N; Marcano T; Guzman M; Moya J; Jurado F; Thompson M; Meechan C; Li D; Schlienger K; Chan I; Sadoff J; Schödel F; Silber JL
    Vaccine; 2007 Mar; 25(11):2139-44. PubMed ID: 17250932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients.
    Chun JY; Kim K; Lee MK; Kang CK; Koh Y; Shin DY; Hong J; Choe PG; Kim NJ; Yoon SS; Park WB; Kim I; Oh MD
    BMC Infect Dis; 2021 Jan; 21(1):117. PubMed ID: 33499826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
    Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
    Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults.
    Choi WS; Choi JH; Choi JY; Eom JS; Kim SI; Pai H; Peck KR; Sohn JW; Cheong HJ
    J Korean Med Sci; 2016 Jan; 31(1):13-7. PubMed ID: 26770032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunogenicity and safety of zoster vaccine in Taiwanese adults.
    Yao CA; Chen LK; Huang KC
    Vaccine; 2015 Mar; 33(13):1515-7. PubMed ID: 25681662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older.
    Choi WS; Choi JH; Jung DS; Choi HJ; Kim YS; Lee J; Jang HC; Shin EC; Park JS; Kim H; Cheong HJ
    Vaccine; 2019 Jun; 37(27):3605-3610. PubMed ID: 31122860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation.
    Miller G; Schaefer H; Yoder S; Miller R; Winokur P; Kotloff K; Klassen D; Wierzbicki M; Amegashie C; Edwards K
    Transpl Infect Dis; 2018 Jun; 20(3):e12874. PubMed ID: 29512282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
    Levin MJ; Schmader KE; Pang L; Williams-Diaz A; Zerbe G; Canniff J; Johnson MJ; Caldas Y; Cho A; Lang N; Su SC; Parrino J; Popmihajlov Z; Weinberg A
    J Infect Dis; 2016 Jan; 213(1):14-22. PubMed ID: 26452397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial.
    Hata A; Inoue F; Hamamoto Y; Yamasaki M; Fujikawa J; Kawahara H; Kawasaki Y; Honjo S; Koshiyama H; Moriishi E; Mori Y; Ohkubo T
    Diabet Med; 2016 Aug; 33(8):1094-101. PubMed ID: 26605507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B; Murray AV; Cheng E; Ifle R; Harvey PR; Tomlinson M; Barben JL; Rarrick K; Stek JE; Chung MO; Schödel FP; Wang WW; Xu J; Chan IS; Silber JL; Schlienger K
    J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial.
    Mullane KM; Morrison VA; Camacho LH; Arvin A; McNeil SA; Durrand J; Campbell B; Su SC; Chan ISF; Parrino J; Kaplan SS; Popmihajlov Z; Annunziato PW;
    Lancet Infect Dis; 2019 Sep; 19(9):1001-1012. PubMed ID: 31399378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
    Dagnew AF; Ilhan O; Lee WS; Woszczyk D; Kwak JY; Bowcock S; Sohn SK; Rodriguez Macías G; Chiou TJ; Quiel D; Aoun M; Navarro Matilla MB; de la Serna J; Milliken S; Murphy J; McNeil SA; Salaun B; Di Paolo E; Campora L; López-Fauqued M; El Idrissi M; Schuind A; Heineman TC; Van den Steen P; Oostvogels L;
    Lancet Infect Dis; 2019 Sep; 19(9):988-1000. PubMed ID: 31399377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.
    Benson CA; Andersen JW; Macatangay BJC; Mailliard RB; Rinaldo CR; Read S; Bozzolo DR; Purdue L; Jennings C; Keefer MC; Glesby M; Tebas P; Russell AF; Martin J; Annunziato P; Popmihajlov Z; Lennox JL
    Clin Infect Dis; 2018 Nov; 67(11):1712-1719. PubMed ID: 29590326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.